This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutInfliximabWhat is infliximabInflammatory Bowel DiseaseMaximising patient outcomes with IBDBiosimilarsWhat is a biosimilarFuture of biosimilarsBiologic switchingINFLECTRA® Introducing INFLECTRA® Position statementsECCOEULARESPGHANDosing & safetyDosingIV dosingAdministration & storageAdministrationStorageSafety informationImportant safety informationConsiderations for SwitchingSwitching to InflectraSafety informationImportant safety informationSafety informationSafety informationClinical evidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceReal-world experienceSummary: real-world evidenceSupporting ResourcesVideosMaterialsPatient Support


Inflectra®(infliximab) Prescribing Information. Adverse events reporting information can be found at the bottom of the page.

 

Considerations for Biologic Switching 

Inflectra/CT-P13* has robust clinical data for switching patients from Remicade®† to Inflectra/CT- P13*.1-10
 

EU and UK guidance supports switching from reference biologics to a biosimilar in appropriate patients.11-14
 

Decisions regarding treatment choice or physician-mediated switching must be a clinical decision made by a treating physician on an individual patient basis, supported by scientific evidence, ensuring safety of patients is not compromised, and with patient awareness.

Watch the video to discover more of the potential benefits of switching to a biosimilar:Header
*CT-P13 is marketed under different brand names including Inflectra and REMSIMA®.
†Remicade® is a registered trademark of MSD.

Return to our Inflectra homepage to explore more about Infliximab 

KickerHeader of this CTA card goes here

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim…

Button

References:

1.Jørgensen KK, et al. Lancet 2017. 389:2304–2316
2.Kim YH, et al. Abstract 101, AOCC 2017.
3.Kim YH, et al. Abstract DOP061. Ecco 2017. J Crohns Colitis. 2017. Supp I.
4.Kim YH, et al. Abstract LB04, UEGW 2017. United European Gastroenterol J. 2017. 5: 1139-40.
5.ClinicalTrials.gov. NCT02096861. [online][viewed: February 2021]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02096861?term=CT-P13.
6.Abstracts of ECCO 2017. J Crohns Colitis 2017; 11/Supp 1 [Alfonso J, et al. Ametzazurra A, et al. P503. Choe YH, et al. P500. Curdia Goncalves T, et al. P472. Fiorino G, et al. P605. Gecse KB, et al. P331. Gonzalez A., et al. P508. Han S, et al. P582. Juan G, et al. P632. Kaniewska M, et al. P425. Kolar M, et al. P532. Lovasz, et al. P592. Molnar, et al. P675. Mortier K, et al. P333. Eberl A, et al. P639. Huoponen S, et al. P685. Smits L, et al. P663. Strik A, et al. P665. Gompertz M, et al. P679. Guerrero Puente LN, et al. P545. Rodriguez Glez GE, et al. P629. St. Clair Jones A, et al. P527. Plevris N, et al. P586. Nugent S, et al. P430. Soret PA, et al. P471. Choe YH, et al. P487. Kamg B, et al. P542. Sladek M, et al. P661. Fiorino G, et al. P633.]
7.Abstracts of ECCO 2016. J Crohns Colitis 2016. 10/Supp 1 [Bortilk M, et al. P495. Carvalho L, et al. P327. Hamanaka S, et al. P329. Kaniewska M, Rydzewska G. P645. Zagorowicz E, et al. P513. Kolar M, et al. DOP032. Diaz Hernandez L, et al. P449. Guerra Veloz MF, et al. P452. Guerra Veloz MF, et al. P600. Muhammed R, et al. P382. Sieczkowska J, et al. P530. Turk N, et al. P577.]
8.Abstracts of BSG 2016. Gut 2016;7/Supp1 [Ala K, et al. PTU-059. Bennett KJ, et al. PWE-017. Chung L, et al. OC-038. RahmanyS, et al. PTU-073.]
9.RazanskaiteV, et al. J Crohns Colitis. 2017. 11(6):690-6.
10.Smits LJ, et al. J Crohns Colitis. 2016. 10:1287-93.
11.Danese S, et al. J Crohns Colitis. 2017. 11(1):26-34.
12.NICE Guidance; Technology appraisal guidance [TA329]. [online][viewed: February 2021]. Available from: https://www.nice.org.uk/guidance/ta329.
13. Lamb CA, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;0:1–106. doi:10.1136/gutjnl-2019-318484.
14. British Society for Rheumatology. Position Statement: Biosimilar Medicines [online]. 2017. https://www.rheumatology.org.uk/Portals/0/Documents/Policy/Position%20statements/Biosimilars.pdf?ver=2019-02-27-170506-670Biosimilars
Browse additional content and information that may be of interest to you  Explore MoreLoading
Learn more about evidence supporting Inflectra.
PP-IFA-GBR-0609. April 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​